Trial Profile
Phase I study for Apatinib combination with intensity-modulated radiotherapy for unresectable hepatocellular carcinoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Aug 2022
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- 15 Jul 2022 Status changed from recruiting to completed as per results published in the BMC Cancer
- 15 Jul 2022 Results published in the BMC Cancer
- 18 Sep 2018 New trial record